About Idera Pharmaceuticals
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company's TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: IDRA
- Previous Close: $1.74
- 50 Day Moving Average: $1.52
- 200 Day Moving Average: $1.81
- 52-Week Range: $1.19 - $3.33
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.14
- P/E Growth: 0.00
- Market Cap: $256.92M
- Outstanding Shares: 147,653,000
- Beta: 2.53
- Net Margins: -4,621.03%
- Return on Equity: -76.66%
- Return on Assets: -68.43%
Companies Related to Idera Pharmaceuticals:
- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 7.07%
- Quick Ratio: 7.06%
What is Idera Pharmaceuticals' stock symbol?
Idera Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDRA."
Where is Idera Pharmaceuticals' stock going? Where will Idera Pharmaceuticals' stock price be in 2017?
3 brokerages have issued 12 month price objectives for Idera Pharmaceuticals' stock. Their forecasts range from $2.10 to $6.00. On average, they expect Idera Pharmaceuticals' share price to reach $4.05 in the next twelve months.
When will Idera Pharmaceuticals announce their earnings?
Idera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
What are analysts saying about Idera Pharmaceuticals stock?
Here are some recent quotes from research analysts about Idera Pharmaceuticals stock:
- Wedbush analysts commented, "IDRA is focused on pursuing an aggressive development strategy for IMO-2125 in light of durable responses in its ongoing Ph 1 study in PD-1 refractory melanoma. We believe the recently presented translational data demonstrating evidence of mechanism support a wider opportunity in improving the response to checkpoint agents in additional immunogenic tumors, as potentially broadening their utility to less immunogenic tumors." (1/31/2017)
According to Zacks Investment Research, "Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate Toll-like Receptors, the body's first line of immune defense. Idera's pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. " (1/30/2017)
Who owns Idera Pharmaceuticals stock?
Idera Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Broadfin Capital LLC (3.00%), FMR LLC (1.70%), State Street Corp (1.05%), Alyeska Investment Group L.P. (0.74%) and Palo Alto Investors LLC (0.42%). Company insiders that own Idera Pharmaceuticals stock include James A Geraghty, Julian Baker, Mark J Casey, Maxine Gowen and Vincent Milano.
Who sold Idera Pharmaceuticals stock? Who is selling Idera Pharmaceuticals stock?
Idera Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC.
Who bought Idera Pharmaceuticals stock? Who is buying Idera Pharmaceuticals stock?
Idera Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Broadfin Capital LLC, Alyeska Investment Group L.P. and State Street Corp. Company insiders that have bought Idera Pharmaceuticals stock in the last two years include James A Geraghty, Julian Baker, Mark J Casey, Maxine Gowen and Vincent Milano.
How do I buy Idera Pharmaceuticals stock?
Shares of Idera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Idera Pharmaceuticals stock cost?
One share of Idera Pharmaceuticals stock can currently be purchased for approximately $1.74.